Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares saw unusually-high trading volume on Friday . Approximately 81,619 shares changed hands during trading, an increase of 47% from the previous session’s volume of 55,625 shares.The stock last traded at $3.05 and had previously closed at $3.03.

AUPH has been the topic of several recent research reports. HC Wainwright initiated coverage on Aurinia Pharmaceuticals in a report on Thursday, June 30th. They set a “buy” rating and a $7.00 target price on the stock. Zacks Investment Research cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, May 5th. Leerink Swann restated an “outperform” rating and set a $7.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 6th. Finally, Canaccord Genuity restated a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Thursday, May 12th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $7.15.

The firm’s market cap is $97.83 million. The company’s 50-day moving average price is $2.87 and its 200-day moving average price is $2.63.

Aurinia Pharmaceuticals Inc (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug, administered twice daily.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.